NEW YORK (GenomeWeb News) – DiagnoCure's fiscal third-quarter revenues increased 143 percent year over year, the Quebec City-based cancer diagnostic firm reported after the close of the market on Thursday.

For the three months ended July 31, revenues totaled C$709,754 (US$722,057), compared to C$292,073 a year ago. Revenues from royalty payments slipped to C$142,102 from C$168,273 a year ago as revenues from Gen-Probe, now part of Hologic, decreased to C$136,843 from C$155,024 a year ago as austerity measures in Europe resulted in softness the region, DiagnoCure said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: oral microbiomes of dogs and their owners, Plasmodium vivax population structure, and more.

The American Society of Human Genetics has issued a position statement on genetic testing of children.

The White House seeks to update how biotechnology products are regulated.

Team science leads some researchers to get lost in the shuffle, the Chronicle of Higher Education reports.